China Jo-Jo Drugstores, Inc. (CJJD)

China Jo-Jo Drugstores, Inc. (CJJD) — VMCI valuation read

Headline read on CJJD: VMCI of 48/100 versus a Healthcare sector median of 50. The 2-point below-median position is what makes China Jo-Jo Drugstores, Inc. a relative-value laggard in the mid-cap cohort, before any pillar-level review.

Form 4 filings on CJJD: zero in the trailing 30 days. The absence of insider transactions is itself a data point, just a low-information one. The thesis runs on financials and price action until that changes.

**Investor frame.** Three reads on CJJD: value (CJJD trades at 23.0x earnings, 28% above the Healthcare median of 18.0x), quality (ROIC of 19.0% sits 9.0pp above the Healthcare median (10.0%)), and risk (net debt to EBITDA of 3.5x is the binding constraint on the bear case). The value read also implies an EV/EBITDA gap of +4.0x against the Healthcare 12.0x baseline.

CJJD rose 2.4% over the trailing 7 days, with a -9.4% read on a 30-day basis.